Page 4 - Michael Yee News Today

The COVID-19 pandemic has served as a pivotal proving ground for the efficacy of messenger RNA (mRNA) vaccines in combating viral outbreaks. However,

The main indexes rallied hard to end the week thanks to Apples $110 billion stock repurchase plan and a big April payrolls miss.

Moderna, Inc. beats earnings expectations. Reported EPS is $-3.07, expectations were $-3.56.

Amgen’s update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.

Schrödinger, Inc. reports earnings inline with expectations. Reported EPS is $-0.76 EPS, expectations were $-0.76.

Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.

MRNA earnings call for the period ending March 31, 2024.

MRNA earnings call for the period ending March 31, 2024.

Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday. Amgen has said it expects to have first-in-human results from a small, early-stage trial of experimental oral compound AMG786 before the end of June. "We are still collecting and analyzing the data," Amgen Chief Scientific Officer Jay Bradner told...

By Deena Beasley (Reuters) - Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly ...